Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Corvus Pharmaceuticals

Nasdaq:CRVS
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRVS
Nasdaq
$69M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • Corvus Pharmaceuticals has significant price volatility in the past 3 months.
CRVS Share Price and Events
7 Day Returns
3.1%
NasdaqGM:CRVS
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-41.3%
NasdaqGM:CRVS
0%
US Biotechs
-11.5%
US Market
CRVS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corvus Pharmaceuticals (CRVS) 3.1% -29.1% -46.7% -41.3% -88.6% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • CRVS underperformed the Biotechs industry which returned 0% over the past year.
  • CRVS underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
CRVS
Industry
5yr Volatility vs Market
Related Companies

CRVS Value

 Is Corvus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Corvus Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $2.36.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corvus Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corvus Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CRVS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.59
NasdaqGM:CRVS Share Price ** NasdaqGM (2020-03-27) in USD $2.36
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corvus Pharmaceuticals.

NasdaqGM:CRVS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CRVS Share Price ÷ EPS (both in USD)

= 2.36 ÷ -1.59

-1.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corvus Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Corvus Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Corvus Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:CRVS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-12.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Corvus Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corvus Pharmaceuticals's assets?
Raw Data
NasdaqGM:CRVS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.54
NasdaqGM:CRVS Share Price * NasdaqGM (2020-03-27) in USD $2.36
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:CRVS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CRVS Share Price ÷ Book Value per Share (both in USD)

= 2.36 ÷ 2.54

0.93x

* Primary Listing of Corvus Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corvus Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Corvus Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Corvus Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CRVS Future Performance

 How is Corvus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corvus Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Corvus Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Corvus Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Corvus Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CRVS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CRVS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -12.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CRVS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CRVS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 114 -89 4
2023-12-31 45 -63 3
2022-12-31 1 -68 4
2021-12-31 0 -61 4
2020-12-31 0 -48 5
2020-03-28
NasdaqGM:CRVS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -37 -47
2019-09-30 -37 -46
2019-06-30 -37 -46
2019-03-31 -39 -44
2018-12-31 -41 -47
2018-09-30 -44 -48
2018-06-30 -44 -51
2018-03-31 -45 -54
2017-12-31 -46 -56
2017-09-30 -45 -55
2017-06-30 -41 -52
2017-03-31 -35 -46

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corvus Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Corvus Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CRVS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Corvus Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRVS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.55 1.36 -2.74 3.00
2023-12-31 -0.82 -0.23 -1.16 3.00
2022-12-31 -1.46 -1.27 -1.65 3.00
2021-12-31 -1.48 -1.32 -1.62 3.00
2020-12-31 -1.42 -1.33 -1.58 3.00
2020-03-28
NasdaqGM:CRVS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.59
2019-09-30 -1.57
2019-06-30 -1.56
2019-03-31 -1.52
2018-12-31 -1.71
2018-09-30 -1.91
2018-06-30 -2.18
2018-03-31 -2.56
2017-12-31 -2.72
2017-09-30 -2.69
2017-06-30 -2.58
2017-03-31 -2.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corvus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corvus Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corvus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CRVS Past Performance

  How has Corvus Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corvus Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corvus Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Corvus Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Corvus Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Corvus Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corvus Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRVS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -46.67 10.88 37.98
2019-09-30 -46.13 11.14 37.45
2019-06-30 -45.63 11.39 36.83
2019-03-31 -44.28 10.98 35.90
2018-12-31 -46.94 10.64 38.59
2018-09-30 -48.36 10.36 39.88
2018-06-30 -50.58 9.80 42.24
2018-03-31 -53.93 10.04 44.91
2017-12-31 -55.66 10.22 46.31
2017-09-30 -54.82 9.84 45.75
2017-06-30 -52.40 10.39 42.72
2017-03-31 -46.06 9.31 37.46
2016-12-31 -36.38 7.62 29.36
2016-09-30 -31.33 7.50 24.33
2016-06-30 -24.18 5.33 19.14
2016-03-31 -35.77 3.96 14.03
2015-12-31 -31.34 2.42 11.35
2015-09-30 -25.45 1.34 6.48
2014-12-31 -0.18 0.13 0.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Corvus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Corvus Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Corvus Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Corvus Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corvus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CRVS Health

 How is Corvus Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corvus Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corvus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corvus Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corvus Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Corvus Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corvus Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:CRVS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 71.11 0.00 77.98
2019-09-30 80.41 0.00 86.42
2019-06-30 89.65 0.00 96.84
2019-03-31 100.70 0.00 105.81
2018-12-31 110.34 0.00 114.60
2018-09-30 118.85 0.00 122.64
2018-06-30 127.40 0.00 133.23
2018-03-31 137.23 0.00 143.93
2017-12-31 84.84 0.00 90.06
2017-09-30 93.74 0.00 99.70
2017-06-30 104.78 0.00 110.33
2017-03-31 118.23 0.00 122.06
2016-12-31 132.80 0.00 134.90
2016-09-30 142.91 0.00 145.12
2016-06-30 151.97 0.00 152.15
2016-03-31 152.55 0.00 152.30
2015-12-31 94.68 0.00 94.39
2015-09-30 100.47 0.00 99.94
2014-12-31 9.85 0.00 12.52
  • Corvus Pharmaceuticals has no debt.
  • Corvus Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Corvus Pharmaceuticals has sufficient cash runway for 2.1 years based on current free cash flow.
  • Corvus Pharmaceuticals has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 24% each year.
X
Financial health checks
We assess Corvus Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corvus Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CRVS Dividends

 What is Corvus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corvus Pharmaceuticals dividends.
If you bought $2,000 of Corvus Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corvus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corvus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CRVS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CRVS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corvus Pharmaceuticals has not reported any payouts.
  • Unable to verify if Corvus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corvus Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corvus Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Corvus Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corvus Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corvus Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CRVS Management

 What is the CEO of Corvus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Miller
COMPENSATION $1,098,039
AGE 68
TENURE AS CEO 6.1 years
CEO Bio

Dr. Richard A. Miller, also known as Rick, M.D., is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Officer, President and Chairman since February 2014 and January 2014 respectively. Dr. Miller has been Chief Commercialization Officer and Research Professor at The University of Texas at Austin since September 2010. Dr. Miller founded Principia Biopharma Inc. in 2008 and served as its President and Chief Executive Officer. He also serves as an Advisor at VantagePoint Capital Partners. In 1992, Dr. Miller founded Pharmacyclics Inc. and was its Chief Executive Officer. Dr. Miller co-founded IDEC Pharmaceuticals Corporation in 1985 and from 1984 to February 1992 served as its Vice President of Research and Clinical. He served as a Director of Principia Biopharma Inc. He has been a Director at Pharmacyclics Inc., since April 1991. He serves as an Executive Director at Corvus Pharmaceuticals, Inc. Dr. Miller served as a Director at Galileo Pharmaceuticals, Inc. and IDEC Pharmaceuticals Corporation. He has been Adjunct Clinical Professor at Medicine in Oncology at Stanford University Medical Center since 1991, where Dr. Miller has ongoing teaching and patient care responsibilities. After receiving an M.D. degree, he continued his career at Stanford as a Research Scientist in Cancer Biology and Immunology where Dr. Miller pioneered the use of monoclonal antibodies for the treatment of lymphomas. He is the author of over 100 scientific publications and numerous issued patents and is a frequently invited speaker at various scientific and business conferences. Dr. Miller received an M.D. degree, summa cum laude, from the State University of New York in 1975 and was trained in Internal Medicine and Medical Oncology at Stanford University Medical Center and is Board Certified in both specialties. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College.

CEO Compensation
  • Rick's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Corvus Pharmaceuticals management team in years:

3.8
Average Tenure
55
Average Age
  • The tenure for the Corvus Pharmaceuticals management team is about average.
Management Team

Rick Miller

TITLE
Co-Founder
COMPENSATION
$1M
AGE
68
TENURE
6.1 yrs

Leiv Lea

TITLE
Chief Financial Officer
COMPENSATION
$750K
AGE
65
TENURE
5.3 yrs

Mehrdad Mobasher

TITLE
VP & Chief Medical Officer
COMPENSATION
$1M
AGE
46
TENURE
1.2 yrs

Joe Buggy

TITLE
Co-Founder & Executive VP of Discovery Research
COMPENSATION
$1M
AGE
52
TENURE
5.3 yrs

Ben Jones

TITLE
Senior Vice President of Pharmaceutical Development
COMPENSATION
$358K
AGE
53
TENURE
1.2 yrs

Dan Hunt

TITLE
Senior VP & Chief Business Officer
COMPENSATION
$2M
AGE
57
TENURE
2.3 yrs

Alan Mendelson

TITLE
Secretary

Stephen Willingham

TITLE
Senior Scientist
Board of Directors Tenure

Average tenure and age of the Corvus Pharmaceuticals board of directors in years:

4.3
Average Tenure
61
Average Age
  • The tenure for the Corvus Pharmaceuticals board of directors is about average.
Board of Directors

Peter Thompson

TITLE
Co-Founder & Independent Director
COMPENSATION
$86K
AGE
59
TENURE
5.3 yrs

Rick Miller

TITLE
Co-Founder
COMPENSATION
$1M
AGE
68
TENURE
6.2 yrs

Terry Gould

TITLE
Independent Director
COMPENSATION
$82K
AGE
62
TENURE
5.3 yrs

Scott Morrison

TITLE
Independent Director
COMPENSATION
$100K
AGE
61
TENURE
4.3 yrs

Steve Krognes

TITLE
Independent Director
COMPENSATION
$90K
AGE
51
TENURE
4.2 yrs

Ian Clark

TITLE
Independent Director
COMPENSATION
$84K
AGE
59
TENURE
3.2 yrs

Lind Grais

TITLE
Independent Director
COMPENSATION
$156K
AGE
63
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Nov 19 Buy Richard Miller Individual 12. Nov 19 13. Nov 19 15,008 $3.00 $45,029
08. Aug 19 Buy OrbiMed Advisors LLC Company 06. Aug 19 06. Aug 19 142,656 $3.51 $500,723
08. Aug 19 Buy Richard Miller Individual 06. Aug 19 07. Aug 19 7,500 $3.58 $26,725
25. Jul 19 Sell Novo Holdings A/S Company 25. Jul 19 25. Jul 19 -1,400,000 $4.00 $-5,600,000
25. Jul 19 Sell Novo Holdings A/S Company 23. Jul 19 24. Jul 19 -92,956 $5.32 $-477,845
01. Jul 19 Buy OrbiMed Advisors LLC Company 27. Jun 19 01. Jul 19 657,344 $3.91 $2,444,065
17. Jun 19 Buy Richard Miller Individual 13. Jun 19 14. Jun 19 12,000 $3.52 $40,874
11. Jun 19 Buy Richard Miller Individual 07. Jun 19 11. Jun 19 15,212 $3.67 $53,039
10. Jun 19 Buy Leiv Lea Individual 06. Jun 19 07. Jun 19 25,500 $3.56 $88,980
X
Management checks
We assess Corvus Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corvus Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CRVS News

Simply Wall St News

Introducing Corvus Pharmaceuticals (NASDAQ:CRVS), The Stock That Slid 64% In The Last Three Years

We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 29% per year, over 3 years. … A Different Perspective Over the last year, Corvus Pharmaceuticals shareholders took a loss of 53%. … Shareholders have lost 29% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges.

Simply Wall St -

Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Corvus Pharmaceuticals, Inc. … The Last 12 Months Of Insider Transactions At Corvus Pharmaceuticals. … Corvus Pharmaceuticals may have bought shares in the last year, but they didn't sell any

Simply Wall St -

How Does Investing In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Impact The Volatility Of Your Portfolio?

(NASDAQ:CRVS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Those Who Purchased Corvus Pharmaceuticals (NASDAQ:CRVS) Shares A Year Ago Have A 58% Loss To Show For It

We wouldn't rush to judgement on Corvus Pharmaceuticals because we don't have a long term history to look at. … Corvus Pharmaceuticals didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … For example, they may be hoping that Corvus Pharmaceuticals comes up with a great new treatment, before it runs out of money.

Simply Wall St -

Does Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Have A High Beta?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Corvus Pharmaceuticals Inc (NASDAQ:CRVS): When Will It Breakeven?

The US$357.91m market-cap company’s loss lessens since it announced a -US$55.66m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$53.93m, as it approaches breakeven. … I’ve put together a brief outline of industry analyst expectations for CRVS, its year of breakeven and its implied growth rate … Check out our latest analysis for Corvus Pharmaceuticals

Simply Wall St -

Corvus Pharmaceuticals Inc's (NASDAQ:CRVS) Profit Outlook

Corvus Pharmaceuticals Inc's (NASDAQ:CRVS): Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. … Check out our latest analysis for Corvus Pharmaceuticals According to the industry analysts covering CRVS, breakeven is near. … Next Steps: There are too many aspects of CRVS to cover in one brief article, but the key fundamentals for the company can all be found in one place – CRVS’s company page on Simply Wall St.

Simply Wall St -

How Do Analysts See Corvus Pharmaceuticals Inc (CRVS) Performing Over The Next Few Years?

Corvus Pharmaceuticals Inc's (NASDAQ:CRVS) latest earnings announcement in September 2017 revealed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts predict Corvus Pharmaceuticals's earnings growth trajectory over the next couple of years and whether the future looks brighter. … The slope of this line is the rate of earnings growth, which in this case is 6.80%. … This means that, we can assume Corvus Pharmaceuticals will grow its earnings by 6.80% every year for the next couple of years.

Simply Wall St -

CRVS Company Info

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Details
Name: Corvus Pharmaceuticals, Inc.
CRVS
Exchange: NasdaqGM
Founded: 2014
$69,211,484
29,326,900
Website: http://www.corvuspharma.com
Address: Corvus Pharmaceuticals, Inc.
863 Mitten Road,
Suite 102,
Burlingame,
California, 94010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CRVS Common Stock Nasdaq Global Market US USD 23. Mar 2016
DB C17 Common Stock Deutsche Boerse AG DE EUR 23. Mar 2016
BRSE C17 Common Stock Berne Stock Exchange CH CHF 23. Mar 2016
Number of employees
Current staff
Staff numbers
53
Corvus Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:09
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/03/09
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.